Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: baricitinib

Baricitinib Promising for Juvenile Idiopathic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting ReportsPediatric Conditions Tagged with:baricitinibEULARflareJIAjuvenile idiopathic arthritis (JIA)PediatricPediatric Rheumatology

Long-Term Safety of Baricitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  December 14, 2020

Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020baricitinibJAK inhibitorRheumatoid Arthritis (RA)

Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2020

The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.

Filed under:Drug Updates Tagged with:baricitinibCOVID-19FDAremdesivirU.S. Food and Drug Administration (FDA)

Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  May 11, 2020

Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…

Filed under:Drug Updates Tagged with:baricitinibCOVID-19Drug SafetyranitidineU.S. Food and Drug Administration (FDA)

Baricitinib: Early vs. Late Treatment Outcomes in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  August 5, 2019

Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:baricitinibEULARRheumatoid Arthritis (RA)

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Lara C. Pullen, PhD  |  June 25, 2019

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabbaricitinibRheumatoid Arthritis (RA)washout

Long-Term Data Show Baricitinib Is Safe & Effective for RA

Michele B. Kaufman, PharmD, BCGP  |  December 17, 2018

Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…

Filed under:Drug Updates Tagged with:baricitinibRheumatoid Arthritis (RA)

Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE

Lara C. Pullen, PhD  |  September 6, 2018

A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:baricitiniborgan damagerashsystemic lupus erythematosus (SLE)

FDA Approves Baricitinib for RA Patients

Michele B. Kaufman, PharmD, BCGP  |  June 25, 2018

The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…

Filed under:Drug Updates Tagged with:baricitinibFDA approvalRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)

FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

Michele B. Kaufman, PharmD, BCGP  |  May 8, 2018

The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibFood and Drug Administrationhemophagocytic lymphohistiocytosisHLHlamotrigineU.S. Food and Drug Administration (FDA)

  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences